Human Papillomavirus Testing in Cervical Cancer Screening

被引：13

作者：

Castle, Philip E. ^{[1
]}

Cremer, Miriam ^{[2
,3
]}

机构：

[1] Global Canc Initiat, Chestertown, MD 21620 USA

[2] Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA

[3] Mt Sinai Med Ctr, Basic Hlth Int, New York, NY 10029 USA

来源：

OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA | 2013年 / 40卷 / 02期

关键词：

Human papillomavirus (HPV); Pap testing; Visual inspection after acetic acid (VIA); Cervical cancer; Cervical intraepithelial neoplasia; Vaccination; Screening; Low-resource settings; HPV-DNA TEST; INTRAEPITHELIAL NEOPLASIA; COST-EFFECTIVENESS; RISK; WOMEN; CYTOLOGY; PRECANCER; PREVENTION; GUIDELINES; AMERICAN;

D O I：

10.1016/j.ogc.2013.03.002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.

引用

页码：377 / +

页数：15

共 56 条

[1]

[Anonymous], 2009, Obstet Gynecol, V114, P1409, DOI 10.1097/AOG.0b013e3181c6f8a4

[2]

[Anonymous], 2012, Obstet Gynecol, V120, P1222

[3]

[Anonymous], 2005, IARC HDB CANC PREVEN, V10

[4] Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme [J].